Today: 22 January 2026
Subscribe
Browse Category

Pfizer News 1 November 2025 - 21 December 2025

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer’s stock is ending 2025 in a familiar place: caught between near-term headwinds (shrinking COVID-era revenue, a growing patent cliff, and U.S. drug-pricing pressure) and a late-decade recovery narrative built around oncology, obesity, and pipeline execution. As of the latest available trade/close data around Dec. 20, Pfizer shares are near $25.19, modestly higher on the most recent session. Investing That…
21 December 2025
····
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Inc. (NYSE: PFE) ended Thursday’s session essentially flat and stayed steady in after-hours trading, a sign that investors are still digesting the company’s newly issued 2026 outlook while watching a fast-evolving U.S. policy backdrop around drug pricing. As of early evening in New York, Pfizer shares were hovering around $25.05 in after-hours trading, after finishing the regular session at…
19 December 2025
····
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. (NYSE: PFE) shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the…
16 December 2025
····
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Inc. (NYSE: PFE) ended Monday’s session on a strong note, then traded slightly lower after the closing bell as investors shifted their attention to the next major catalyst: Pfizer’s scheduled analyst call Tuesday morning, where management is expected to outline full-year 2026 financial guidance. Yahoo Finance In regular trading, Pfizer shares closed at $26.43, up 2.24% on the day.…
16 December 2025
····
Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer, Inc. (NYSE: PFE) is back in focus on Monday, December 15, 2025, with investors weighing fresh collaboration news, a looming guidance event, and a familiar debate: is Pfizer stock a high-yield value play with a rebuilding pipeline—or a “wait-and-see” story facing years of patent headwinds? As of Monday’s session, Pfizer stock is trading around $26.36. That places PFE near…
15 December 2025
····
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Inc. (NYSE: PFE) enters the new week with its stock hovering around $25.85 in early Monday trading, as investors weigh a familiar late-2025 mix: a high dividend, a rebuilding growth story after the COVID boom, and a pipeline/M&A strategy designed to refill the revenue engine ahead of major patent cliffs. The immediate spotlight is tomorrow morning’s full-year 2026 guidance…
15 December 2025
····
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Inc. (NYSE: PFE) heads into the new trading week with investors balancing two very different storylines: a steady, high-yield “value pharma” profile versus a news-driven catalyst tape around obesity deals, oncology data, cost cuts, and shifting U.S. COVID-vaccine policy. As of the latest close, Pfizer shares were around $25.85. With markets closed on Sunday (Dec. 14), the next big…
14 December 2025
····
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. (NYSE: PFE) finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market session opening on December 10, 2025, traders in Pfizer stock are lining up the key catalysts that could drive PFE’s…
10 December 2025
···
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic pipeline. This article pulls together the most relevant current Pfizer stock news as of November 30, 2025, and explains what…
30 November 2025
····
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance (around $26–$27). Notably,…
1 November 2025
···
1 2

Stock Market Today

  • iShares 0-3 Month Treasury Bond ETF Sees $558 Million Inflow, Shares Increase 2.5%
    January 22, 2026, 11:11 AM EST. The iShares 0-3 Month Treasury Bond ETF (SGOV) recorded a significant inflow of approximately $558 million this week, marking a 2.5% increase in units outstanding from 220.3 million to 225.85 million. This surge reflects heightened investor demand for short-term U.S. Treasury securities, often favored for safety amid market volatility. SGOV's share price last traded at $100.57, fitting within its 52-week range of $100.04 to $100.75. An increase in ETF units indicates more underlying government bonds had to be purchased, affecting those markets. Investors watch such inflows as indicators of risk sentiment and capital shifts toward secure assets.
Go toTop